Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20241231-00868
Endovascular treatment has become the primary treatment for patients with acute ischemic stroke (AIS) due to large vessel occlusion. Its development and clinical application have expanded significantly in recent years. Imaging assessment plays a pivotal role in guiding both preoperative screening and postoperative management in AIS patients undergoing such interventions. However, updated expert consensus and standardized guidelines remain lacking. To address this gap, the Professional Committee of Interventional Neurology of the Chinese Research Hospital Association convened leading cerebrovascular disease experts to formulate consensus recommendations based on domestic clinical practice, aiming to provide authoritative guidance for imaging evaluation in this patient population.
{"title":"[Expert consensus on imaging evaluation of early endovascular treatment of acute ischemic stroke].","authors":"","doi":"10.3760/cma.j.cn112138-20241231-00868","DOIUrl":"10.3760/cma.j.cn112138-20241231-00868","url":null,"abstract":"<p><p>Endovascular treatment has become the primary treatment for patients with acute ischemic stroke (AIS) due to large vessel occlusion. Its development and clinical application have expanded significantly in recent years. Imaging assessment plays a pivotal role in guiding both preoperative screening and postoperative management in AIS patients undergoing such interventions. However, updated expert consensus and standardized guidelines remain lacking. To address this gap, the Professional Committee of Interventional Neurology of the Chinese Research Hospital Association convened leading cerebrovascular disease experts to formulate consensus recommendations based on domestic clinical practice, aiming to provide authoritative guidance for imaging evaluation in this patient population.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"723-735"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20250515-00279
Combination therapies involving oral anti-diabetic agents with complementary mechanisms of action are widely employed in the clinical management of type 2 diabetes mellitus (T2DM). Initiating combination therapy early-either at diagnosis or through timely escalation from monotherapy-can expedite achievement of individualized glycemic targets and slow disease progression in newly diagnosed patients. The inclusion of agents with weight-reducing properties is particularly beneficial for overweight or obese individuals, as it enhances insulin sensitivity and facilitates glycemic control. Moreover, selecting combinations with proven cardiovascular and renal benefits offers long-term organ protection and improves overall prognosis. This consensus statement provides guidance on the optimal use of oral combination therapies for effective and individualized management of T2DM in clinical practice.
{"title":"[Expert consensus on combination therapies of oral anti-diabetic drugs for adults with type 2 diabetes (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112138-20250515-00279","DOIUrl":"10.3760/cma.j.cn112138-20250515-00279","url":null,"abstract":"<p><p>Combination therapies involving oral anti-diabetic agents with complementary mechanisms of action are widely employed in the clinical management of type 2 diabetes mellitus (T2DM). Initiating combination therapy early-either at diagnosis or through timely escalation from monotherapy-can expedite achievement of individualized glycemic targets and slow disease progression in newly diagnosed patients. The inclusion of agents with weight-reducing properties is particularly beneficial for overweight or obese individuals, as it enhances insulin sensitivity and facilitates glycemic control. Moreover, selecting combinations with proven cardiovascular and renal benefits offers long-term organ protection and improves overall prognosis. This consensus statement provides guidance on the optimal use of oral combination therapies for effective and individualized management of T2DM in clinical practice.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"707-722"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20241101-00722
Y Q Fang, G Jia, Y S Liu, L N Cui, Y L Shang, Y Han
Objective: To evaluate the quality of information on autoimmune liver disease in videos on the TikTok short video platform. Methods: The keyword "autoimmune liver disease" was used to search the top 200 videos on TikTok in the default sorting order. Using the DISCERN video quality assessment tool and the structured content integrity evaluation tool, we assessed the quality of the information in each video in relation to the pertinent disease guidelines. Furthermore, we investigated any relationships between the quality of the videos and their characteristics (likes, comments, retweets, days and duration of uploading). Results: A total of 140 videos were included, 96.4% of which were provided by medical professionals. The content completeness scores for each dimension were as follows: definition, 1.0 (0.0, 1.0); symptoms, 0.0 (0.0, 1.0); risk factors, 0.0 (0.0, 0.5); assessment, 0.5 (0.0, 1.5); management, 0.5 (0.0, 1.0); and outcome, 0.0 (0.0, 1.0). Furthermore, 91.4% of videos with DISCERN scores of ≤50 were of "fair" quality or below. Additionally, the difference in DISCERN scores between videos from different publishers was not statistically significant (P>0.05). The number of likes, comments, favorites, retweets, and video duration had a strong positive correlation with the overall DISCERN score (r=0.17, 0.18, 0.25, 0.26, 0.44, all P<0.05). Conclusions: The overall quality of videos related to autoimmune liver disease on the TikTok video platform is low. Therefore, publishers should focus on the comprehensiveness and accuracy of the information. Additionally, the TikTok platform should optimize its video review mechanism to provide the public with more accurate and reliable health information.
{"title":"[Evaluation of information quality in autoimmune liver disease-related videos on TikTok].","authors":"Y Q Fang, G Jia, Y S Liu, L N Cui, Y L Shang, Y Han","doi":"10.3760/cma.j.cn112138-20241101-00722","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20241101-00722","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the quality of information on autoimmune liver disease in videos on the TikTok short video platform. <b>Methods:</b> The keyword \"autoimmune liver disease\" was used to search the top 200 videos on TikTok in the default sorting order. Using the DISCERN video quality assessment tool and the structured content integrity evaluation tool, we assessed the quality of the information in each video in relation to the pertinent disease guidelines. Furthermore, we investigated any relationships between the quality of the videos and their characteristics (likes, comments, retweets, days and duration of uploading). <b>Results:</b> A total of 140 videos were included, 96.4% of which were provided by medical professionals. The content completeness scores for each dimension were as follows: definition, 1.0 (0.0, 1.0); symptoms, 0.0 (0.0, 1.0); risk factors, 0.0 (0.0, 0.5); assessment, 0.5 (0.0, 1.5); management, 0.5 (0.0, 1.0); and outcome, 0.0 (0.0, 1.0). Furthermore, 91.4% of videos with DISCERN scores of ≤50 were of \"fair\" quality or below. Additionally, the difference in DISCERN scores between videos from different publishers was not statistically significant (<i>P></i>0.05). The number of likes, comments, favorites, retweets, and video duration had a strong positive correlation with the overall DISCERN score (<i>r</i>=0.17, 0.18, 0.25, 0.26, 0.44, all <i>P</i><0.05). <b>Conclusions:</b> The overall quality of videos related to autoimmune liver disease on the TikTok video platform is low. Therefore, publishers should focus on the comprehensiveness and accuracy of the information. Additionally, the TikTok platform should optimize its video review mechanism to provide the public with more accurate and reliable health information.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"759-765"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20250401-00192
Y P Wang, J Wang, Y M Mu
{"title":"[The role of continuous glucose monitoring in diabetes screening and glycemic optimization].","authors":"Y P Wang, J Wang, Y M Mu","doi":"10.3760/cma.j.cn112138-20250401-00192","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20250401-00192","url":null,"abstract":"","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"701-706"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20241129-00787
L R Chen, C Y Li, D Wang, Q Liu, X N Liang, Y Yao, Y X Luo, J Song, Q Li, X L Zhang
Objective: To explore the relationship between intestinal bacterial overgrowth (SIBO) and ulcerative colitis (UC). Methods: From December 2023 to June 2024, 85 patients with UC from the Gastroenterology Department of the Luquan branch of the Second Hospital of Hebei Medical University were enrolled. The lactulose hydrogen-methane breath test was performed to assess the prevalence of SIBO. Clinical data, including basic information, clinical manifestations, endoscopic manifestations, inflammatory indicators, current medication regimen, and past medical history, were collected. Furthermore, the body mass index (BMI), modified Mayo score, and patient-reported outcome (PRO2) score were calculated to evaluate disease activity in each patient. The Student's t-test, Chi-square test, non-parametric test, and multiple logistic regression were used to analyze the data and explore the relationship between SIBO and UC. Results: The incidence of abdominal pain and bloating in patients who were SIBO positive with UC was higher than in those who were SIBO negative [abdominal pain: 50.0%(10/20) vs. 23.1%(15/65), χ²=5.34, P=0.021; abdominal distension: 40.0% (8/20) vs. 13.8% (9/65), χ²=5.01, P=0.025]; the difference was statistically significant (P<0.05). Patients who were SIBO positive with UC were more likely to develop hypoproteinemia and anemia than those who were SIBO negative [hypoproteinemia: 50.0% (10/20) vs. 15.4% (10/65), χ²=8.35, P=0.004; anemia: 35.0% (7/20) vs. 9.2% (6/65), χ²=5.98, P=0.014]; the difference was statistically significant (P<0.05). In the intestinal methanogen overgrowth (IMO) positive group, the number of patients with UC with 1-2 stool times/day was higher, and the distribution of stool times between the IMO positive and IMO negative groups was significantly different (χ2=6.45, P=0.040). Furthermore, combined hypoproteinemia and anemia were risk factors for SIBO in patients with UC (hypoproteinemia OR=4.331, 95%CI 1.117-16.799, P=0.034; anemia OR=5.515, 95%CI 1.231-24.700, P=0.026). Conclusions: We observed a clinical overlap between SIBO and UC. SIBO could be targeted to optimize the treatment of patients with UC in the future.
{"title":"[Clinical features of ulcerative colitis in patients with small intestinal bacterial overgrowth].","authors":"L R Chen, C Y Li, D Wang, Q Liu, X N Liang, Y Yao, Y X Luo, J Song, Q Li, X L Zhang","doi":"10.3760/cma.j.cn112138-20241129-00787","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20241129-00787","url":null,"abstract":"<p><p><b>Objective:</b> To explore the relationship between intestinal bacterial overgrowth (SIBO) and ulcerative colitis (UC). <b>Methods:</b> From December 2023 to June 2024, 85 patients with UC from the Gastroenterology Department of the Luquan branch of the Second Hospital of Hebei Medical University were enrolled. The lactulose hydrogen-methane breath test was performed to assess the prevalence of SIBO. Clinical data, including basic information, clinical manifestations, endoscopic manifestations, inflammatory indicators, current medication regimen, and past medical history, were collected. Furthermore, the body mass index (BMI), modified Mayo score, and patient-reported outcome (PRO2) score were calculated to evaluate disease activity in each patient. The Student's <i>t</i>-test, Chi-square test, non-parametric test, and multiple logistic regression were used to analyze the data and explore the relationship between SIBO and UC. <b>Results:</b> The incidence of abdominal pain and bloating in patients who were SIBO positive with UC was higher than in those who were SIBO negative [abdominal pain: 50.0%(10/20) vs. 23.1%(15/65), <i>χ</i>²=5.34, <i>P</i>=0.021; abdominal distension: 40.0% (8/20) vs. 13.8% (9/65), <i>χ</i>²=5.01, <i>P</i>=0.025]; the difference was statistically significant (<i>P<</i>0.05). Patients who were SIBO positive with UC were more likely to develop hypoproteinemia and anemia than those who were SIBO negative [hypoproteinemia: 50.0% (10/20) vs. 15.4% (10/65), <i>χ</i>²=8.35, <i>P</i>=0.004; anemia: 35.0% (7/20) vs. 9.2% (6/65), <i>χ</i>²=5.98, <i>P</i>=0.014]; the difference was statistically significant (<i>P</i><0.05). In the intestinal methanogen overgrowth (IMO) positive group, the number of patients with UC with 1-2 stool times/day was higher, and the distribution of stool times between the IMO positive and IMO negative groups was significantly different (<i>χ</i><sup>2</sup>=6.45, <i>P=</i>0.040). Furthermore, combined hypoproteinemia and anemia were risk factors for SIBO in patients with UC (hypoproteinemia <i>OR=</i>4.331, 95%<i>CI</i> 1.117-16.799, <i>P</i>=0.034; anemia <i>OR</i>=5.515, 95%<i>CI</i> 1.231-24.700, <i>P</i>=0.026). <b>Conclusions:</b> We observed a clinical overlap between SIBO and UC. SIBO could be targeted to optimize the treatment of patients with UC in the future.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"753-758"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.3760/cma.j.cn112138-20250115-00040
H Z Liu, X L Zhang, S Dong, X J Li, X M Fu, Y H Wang, X D Hu, B Li, Z H Lyu
Objective: To examine the interaction between gender and the visceral adiposity index (VAI) in relation to the risk of type 2 diabetes mellitus (T2DM). Methods: This retrospective cohort study utilized data from the public Dryad database derived from the NAGALA (NAFLD in the Gifu Area, Longitudinal Analysis) project (1994-2016). Participants were stratified into quartiles based on VAI levels. A multivariate Cox proportional hazards regression model was employed to evaluate whether VAI independently predicts T2DM risk. Kaplan-Meier survival curves and receiver operating characteristic (ROC) curves were constructed for each VAI quartile. Subgroup analyses were conducted to examine associations across age and body mass index categories. Both multiplicative and additive interaction effects between gender and VAI were assessed. Additionally, gender-specific Cox models were fitted to further explore these associations. Results: A total of 15 453 participants [8 419 males and 7 034 females; mean age, (43.7±8.9) years] were included, with a median follow-up duration of 5.39 years. During follow-up, 373 participants (2.4%) developed T2DM. After adjustment for potential confounders, higher VAI levels were independently associated with increased T2DM risk (HR=1.16; 95%CI 1.11-1.21), consistent with the results across VAI quartiles. Kaplan-Meier analysis revealed a significant trend of increasing T2DM incidence across VAI quartiles (P<0.001). The area under the ROC curve for VAI in predicting T2DM at 3, 5, and 10 years was 0.755, 0.735, and 0.696, respectively. Sensitivity analyses showed that elevated VAI was associated with increased T2DM risk across all age and body mass index subgroups (all P<0.05). Regarding interaction analysis, the HR (95%CI) for the multiplicative interaction between VAI and gender was 1.22 (1.19-1.26). The relative excess risk of interaction was -1.08 (95%CI -2.96 to -0.06), the attributable proportion of interaction was -0.54 (95%CI -1.35 to -0.01), and the synergy index was 0.48 (95%CI 0.26-0.91), indicating a negative additive interaction. Using low-VAI women as the reference group, the risk of T2DM in high-VAI women was higher (HR=2.53, 95%CI 1.59-4.02) compared to high-VAI men (HR=2.01, 95%CI 1.49-2.72). In gender-specific analyses, increasing VAI remained significantly associated with elevated T2DM risk after adjustment in both females (HR=1.43, 95%CI 1.21-1.68) and males (HR=1.16; 95%CI 1.11-1.22), with consistent findings across VAI quartiles. Conclusions: VAI and gender demonstrated multiplicative and additive interaction in relation to T2DM risk. The association between increasing VAI and T2DM risk was more pronounced in women than in men.
{"title":"[Interaction between gender and visceral adiposity index-associated risk of type 2 diabetes].","authors":"H Z Liu, X L Zhang, S Dong, X J Li, X M Fu, Y H Wang, X D Hu, B Li, Z H Lyu","doi":"10.3760/cma.j.cn112138-20250115-00040","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20250115-00040","url":null,"abstract":"<p><p><b>Objective:</b> To examine the interaction between gender and the visceral adiposity index (VAI) in relation to the risk of type 2 diabetes mellitus (T2DM). <b>Methods:</b> This retrospective cohort study utilized data from the public Dryad database derived from the NAGALA (NAFLD in the Gifu Area, Longitudinal Analysis) project (1994-2016). Participants were stratified into quartiles based on VAI levels. A multivariate Cox proportional hazards regression model was employed to evaluate whether VAI independently predicts T2DM risk. Kaplan-Meier survival curves and receiver operating characteristic (ROC) curves were constructed for each VAI quartile. Subgroup analyses were conducted to examine associations across age and body mass index categories. Both multiplicative and additive interaction effects between gender and VAI were assessed. Additionally, gender-specific Cox models were fitted to further explore these associations. <b>Results:</b> A total of 15 453 participants [8 419 males and 7 034 females; mean age, (43.7±8.9) years] were included, with a median follow-up duration of 5.39 years. During follow-up, 373 participants (2.4%) developed T2DM. After adjustment for potential confounders, higher VAI levels were independently associated with increased T2DM risk (<i>HR</i>=1.16; 95%<i>CI</i> 1.11-1.21), consistent with the results across VAI quartiles. Kaplan-Meier analysis revealed a significant trend of increasing T2DM incidence across VAI quartiles (<i>P</i><0.001). The area under the ROC curve for VAI in predicting T2DM at 3, 5, and 10 years was 0.755, 0.735, and 0.696, respectively. Sensitivity analyses showed that elevated VAI was associated with increased T2DM risk across all age and body mass index subgroups (all <i>P</i><0.05). Regarding interaction analysis, the <i>HR</i> (95%<i>CI</i>) for the multiplicative interaction between VAI and gender was 1.22 (1.19-1.26). The relative excess risk of interaction was -1.08 (95%<i>CI</i> -2.96 to -0.06), the attributable proportion of interaction was -0.54 (95%<i>CI</i> -1.35 to -0.01), and the synergy index was 0.48 (95%<i>CI</i> 0.26-0.91), indicating a negative additive interaction. Using low-VAI women as the reference group, the risk of T2DM in high-VAI women was higher (<i>HR</i>=2.53, 95%<i>CI</i> 1.59-4.02) compared to high-VAI men (<i>HR</i>=2.01, 95%<i>CI</i> 1.49-2.72). In gender-specific analyses, increasing VAI remained significantly associated with elevated T2DM risk after adjustment in both females (<i>HR=</i>1.43, 95%<i>CI</i> 1.21-1.68) and males (<i>HR</i>=1.16; 95%<i>CI</i> 1.11-1.22), with consistent findings across VAI quartiles. <b>Conclusions:</b> VAI and gender demonstrated multiplicative and additive interaction in relation to T2DM risk. The association between increasing VAI and T2DM risk was more pronounced in women than in men.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 8","pages":"736-744"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.3760/cma.j.cn112138-20240924-00601
J X Yan, X Y Bai, H Liang, F R Zhang, Y L Miao, J K Niu
<p><p><b>Objective:</b> This study aimed to investigate the role of heat shock protein family A member 5 (HSPA5) in ferroptosis at its regulatory mechanisms in ulcerative colitis (UC), using both a dextran sulfate sodium (DSS)-induced mouse model of acute colitis and in vitro cell experiments. <b>Methods:</b> Differentially expressed genes in UC were identified using the GSE87466 dataset from the Gene Expression Omnibus, cross-referenced with the ferroptosis-related gene database FerrDB (version 2). A protein-protein interaction (PPI) network was constructed, identifying HSPA5 as a core hub gene. To validate its role in vivo, acute colitis was induced in C57BL/6 mice using DSS, followed by treatment with the ferroptosis inhibitor Ferrostatin-1 (Fer-1). Lipid peroxidation and ferroptosis levels were assessed by measuring malondialdehyde (MDA) and iron content in colon tissues. The expression of ferroptosis-related proteins, including prostaglandin-endoperoxide synthase 2 (PTGS2), glutathione peroxidase 4 (GPX4), ferritin light chain (FTL), activating transcription factor 4 (ATF4), and HSPA5, in addition to tight junction proteins ZO-1 and Occludin, were evaluated using immunohistochemistry and Western blotting. In vitro, an inflammatory model was established using lipopolysaccharide (LPS)-stimulated Caco-2 cells. Lentiviral knockdown of HSPA5 was performed to assess its regulatory effects on ferroptosis by assessing MDA levels, GPX4 activity, and the expression of related proteins. Statistical analyses were conducted with SPSS (version 29.1), with <i>t</i>-tests or one-way ANOVA for normally distributed data and the Mann-Whitney <i>U</i> test for ordinal data. Statistical significance was set at <i>P</i><0.05. <b>Results:</b> Based on the PPI analysis and previous research, HSPA5 emerged as a key gene linking UC and ferroptosis. In DSS-treated mice, colonic injury was accompanied by elevated MDA levels (<i>t</i>=5.72, <i>P</i><0.001) and iron accumulation (<i>t</i>=6.32, <i>P</i><0.001). DSS also increased the expression of PTGS2 and proteins in the ATF4-HSPA5 pathway, while reducing the levels of GPX4, FTL, ZO-1, and Occludin. These findings could be partially reversed by Fer-1 (MDA: <i>t</i>=2.92, <i>P</i><0.05; iron: <i>t</i>=5.84, <i>P</i><0.001). In Caco-2 cells, LPS treatment elevated the expression of PTGS2, ATF4, and HSPA5, and elevated the MDA content (<i>t</i>=9.63, <i>P</i><0.001), while reducing the expression of FTL, GPX4, ZO-1, and Occludin, as well as GPX4 enzyme activity (<i>t</i>=-11.20, <i>P</i><0.001). Knockdown of HSPA5 further exacerbated these changes, significantly increasing MDA levels (<i>t</i>=4.15, <i>P</i><0.01), decreasing GPX4 activity (<i>t</i>=-9.81, <i>P</i><0.001), and altering ferroptosis-related protein expression. <b>Conclusion:</b> HSPA5 appears to protect against intestinal damage in UC by enhancing GPX4 expression and activity, thereby reducing ferroptosis and preserving epithelial barrier integrity through
{"title":"[Heat shock protein family A member 5 regulation of ferroptosis alleviates acute-phase mucosal injury in ulcerative colitis].","authors":"J X Yan, X Y Bai, H Liang, F R Zhang, Y L Miao, J K Niu","doi":"10.3760/cma.j.cn112138-20240924-00601","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20240924-00601","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to investigate the role of heat shock protein family A member 5 (HSPA5) in ferroptosis at its regulatory mechanisms in ulcerative colitis (UC), using both a dextran sulfate sodium (DSS)-induced mouse model of acute colitis and in vitro cell experiments. <b>Methods:</b> Differentially expressed genes in UC were identified using the GSE87466 dataset from the Gene Expression Omnibus, cross-referenced with the ferroptosis-related gene database FerrDB (version 2). A protein-protein interaction (PPI) network was constructed, identifying HSPA5 as a core hub gene. To validate its role in vivo, acute colitis was induced in C57BL/6 mice using DSS, followed by treatment with the ferroptosis inhibitor Ferrostatin-1 (Fer-1). Lipid peroxidation and ferroptosis levels were assessed by measuring malondialdehyde (MDA) and iron content in colon tissues. The expression of ferroptosis-related proteins, including prostaglandin-endoperoxide synthase 2 (PTGS2), glutathione peroxidase 4 (GPX4), ferritin light chain (FTL), activating transcription factor 4 (ATF4), and HSPA5, in addition to tight junction proteins ZO-1 and Occludin, were evaluated using immunohistochemistry and Western blotting. In vitro, an inflammatory model was established using lipopolysaccharide (LPS)-stimulated Caco-2 cells. Lentiviral knockdown of HSPA5 was performed to assess its regulatory effects on ferroptosis by assessing MDA levels, GPX4 activity, and the expression of related proteins. Statistical analyses were conducted with SPSS (version 29.1), with <i>t</i>-tests or one-way ANOVA for normally distributed data and the Mann-Whitney <i>U</i> test for ordinal data. Statistical significance was set at <i>P</i><0.05. <b>Results:</b> Based on the PPI analysis and previous research, HSPA5 emerged as a key gene linking UC and ferroptosis. In DSS-treated mice, colonic injury was accompanied by elevated MDA levels (<i>t</i>=5.72, <i>P</i><0.001) and iron accumulation (<i>t</i>=6.32, <i>P</i><0.001). DSS also increased the expression of PTGS2 and proteins in the ATF4-HSPA5 pathway, while reducing the levels of GPX4, FTL, ZO-1, and Occludin. These findings could be partially reversed by Fer-1 (MDA: <i>t</i>=2.92, <i>P</i><0.05; iron: <i>t</i>=5.84, <i>P</i><0.001). In Caco-2 cells, LPS treatment elevated the expression of PTGS2, ATF4, and HSPA5, and elevated the MDA content (<i>t</i>=9.63, <i>P</i><0.001), while reducing the expression of FTL, GPX4, ZO-1, and Occludin, as well as GPX4 enzyme activity (<i>t</i>=-11.20, <i>P</i><0.001). Knockdown of HSPA5 further exacerbated these changes, significantly increasing MDA levels (<i>t</i>=4.15, <i>P</i><0.01), decreasing GPX4 activity (<i>t</i>=-9.81, <i>P</i><0.001), and altering ferroptosis-related protein expression. <b>Conclusion:</b> HSPA5 appears to protect against intestinal damage in UC by enhancing GPX4 expression and activity, thereby reducing ferroptosis and preserving epithelial barrier integrity through ","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 7","pages":"643-651"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.3760/cma.j.cn112138-20250422-00231
Obesity is a significant public health problem in China. The development of a proactive and effective model to combat the obesity epidemic could alleviate the disease burden, improve population health, and ultimately support the achievement of the Healthy China goals. Obesity research has made significant progress domestically and internationally, resulting in continuous improvements in basic public health services within primary care. Therefore, the National Office of Basic Public Health Service Program for Primary Diabetes Care has organized experts to issue the National Guidelines for the Integrated Management of Obesity in Primary Care (2025). The aim of this guide is to assist primary care physicians with evidence-based recommendations for diagnosing and evaluating obesity, promoting standardized and integrated management for patients with obesity. It includes essential guidelines for patient management, an overview of obesity, diagnostic and evaluation criteria, integrated management strategies, and protocols for follow-up and referral.
{"title":"[National guidelines for the integrated management of obesity in primary care (2025)].","authors":"","doi":"10.3760/cma.j.cn112138-20250422-00231","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20250422-00231","url":null,"abstract":"<p><p>Obesity is a significant public health problem in China. The development of a proactive and effective model to combat the obesity epidemic could alleviate the disease burden, improve population health, and ultimately support the achievement of the Healthy China goals. Obesity research has made significant progress domestically and internationally, resulting in continuous improvements in basic public health services within primary care. Therefore, the National Office of Basic Public Health Service Program for Primary Diabetes Care has organized experts to issue the National Guidelines for the Integrated Management of Obesity in Primary Care (2025). The aim of this guide is to assist primary care physicians with evidence-based recommendations for diagnosing and evaluating obesity, promoting standardized and integrated management for patients with obesity. It includes essential guidelines for patient management, an overview of obesity, diagnostic and evaluation criteria, integrated management strategies, and protocols for follow-up and referral.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 7","pages":"604-613"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.3760/cma.j.cn112138-20241121-00773
X Y Cheng, S Qian, X L Lou, J Y Jin, J R Zhang, C J Mao, C F Liu
<p><p><b>Objective:</b> To observe the characteristics of gastrointestinal tract symptoms in patients with Parkinson's disease (PD) and analyze the characteristics of these symptoms in patients with different PD subtypes. <b>Methods:</b> A total of 297 PD patients who were admitted to the Neurology Department of the Second Affiliated Hospital of Soochow University from November 2022 to March 2024 were enrolled. The gastrointestinal symptoms of PD patients were evaluated using Drooling Severity and Frequency Scale (DSFS), Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD), Drooling Rating Scale (DRS), Eating Assessment Tool 10 (EAT-10), Gastroparesis Cardinal Symptom Index (GCSI), and Rome Ⅳ diagnostic criteria. The patients were grouped based on the presence or absence of gastrointestinal symptoms. Additionally, they were stratified according to disease duration (≤2 years, 2-5 years, 5-10 years, and>10 years) and motor symptom subtype [tremor-dominant (TD) vs. postural instability and gait difficulty (PIGD)]. One-way ANOVA and logistic regression analysis were applied to examine between-group differences while Spearman correlation analysis was employed to assess correlations between clinical symptoms. <b>Results:</b> The average age of the patients with PD was 67.0 (60.0, 72.0) years, and 161 (54.2%) were male. The incidence of PD combined with gastrointestinal symptoms was, in descending order: constipation (191, 64.3%), salivation (155, 52.2%), gastroparesis (93, 31.3%), and dysphagia (68, 22.9%). Compared with PD patients without gastrointestinal symptoms, those with symptoms had higher scores in the RBD-HK [12.0 (5.0, 21.5) vs. 5.0 (0.0, 9.0), <i>Z=</i>-3.74, <i>P=</i>0.017], ESS [6.0 (2.0, 12.0) vs. 3.0 (0.0, 6.0), <i>Z</i>=-3.20, <i>P</i>=0.023], and MDS-UPDRS Part Ⅰ [9.0 (5.0, 14.0) vs. 5.0 (2.3, 9.0), <i>Z</i>=-3.61, <i>P</i>=0.014]. The severity of sialorrhea and deglutition disorders, along with the incidence of constipation, all increased with longer disease duration. Patients with the PIGD subtype had higher GCSI scores than those with the TD subtype [0.0 (0.0, 1.9) vs. 0.0 (0.0, 0.0), <i>Z</i>=-3.57, <i>P</i>=0.007]. Across the cohort, sialorrhea, deglutition disorders, gastroparesis, and constipation were positively associated with the H-Y stage, MDS-UPDRS Ⅰ, HAMD, NMSQ, and SCOPA-AUT; EAT-10 scores were negatively correlated with MoCA (<i>r</i>=-0.171, <i>P<</i>0.05); and GCSI scores were negatively correlated with MMSE and MoCA (<i>r</i>=-0.154, <i>r</i>=-0.169, both <i>P</i><0.05). <b>Conclusions:</b> Overall, 84.5% of the patients with PD had one or more gastrointestinal symptoms, and the incidence and severity of gastrointestinal symptoms increased with disease duration. The severity of gastroparesis was higher in the PIGD group than in the TD group. The scores of all gastrointestinal symptoms were positively correlated with the H-Y stage and MDS-UPDRS Ⅰ, while the GCSI scores were negatively correlated with the cogniti
{"title":"[Analysis of gastrointestinal tract symptoms and related factors in patients with Parkinson's disease].","authors":"X Y Cheng, S Qian, X L Lou, J Y Jin, J R Zhang, C J Mao, C F Liu","doi":"10.3760/cma.j.cn112138-20241121-00773","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20241121-00773","url":null,"abstract":"<p><p><b>Objective:</b> To observe the characteristics of gastrointestinal tract symptoms in patients with Parkinson's disease (PD) and analyze the characteristics of these symptoms in patients with different PD subtypes. <b>Methods:</b> A total of 297 PD patients who were admitted to the Neurology Department of the Second Affiliated Hospital of Soochow University from November 2022 to March 2024 were enrolled. The gastrointestinal symptoms of PD patients were evaluated using Drooling Severity and Frequency Scale (DSFS), Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD), Drooling Rating Scale (DRS), Eating Assessment Tool 10 (EAT-10), Gastroparesis Cardinal Symptom Index (GCSI), and Rome Ⅳ diagnostic criteria. The patients were grouped based on the presence or absence of gastrointestinal symptoms. Additionally, they were stratified according to disease duration (≤2 years, 2-5 years, 5-10 years, and>10 years) and motor symptom subtype [tremor-dominant (TD) vs. postural instability and gait difficulty (PIGD)]. One-way ANOVA and logistic regression analysis were applied to examine between-group differences while Spearman correlation analysis was employed to assess correlations between clinical symptoms. <b>Results:</b> The average age of the patients with PD was 67.0 (60.0, 72.0) years, and 161 (54.2%) were male. The incidence of PD combined with gastrointestinal symptoms was, in descending order: constipation (191, 64.3%), salivation (155, 52.2%), gastroparesis (93, 31.3%), and dysphagia (68, 22.9%). Compared with PD patients without gastrointestinal symptoms, those with symptoms had higher scores in the RBD-HK [12.0 (5.0, 21.5) vs. 5.0 (0.0, 9.0), <i>Z=</i>-3.74, <i>P=</i>0.017], ESS [6.0 (2.0, 12.0) vs. 3.0 (0.0, 6.0), <i>Z</i>=-3.20, <i>P</i>=0.023], and MDS-UPDRS Part Ⅰ [9.0 (5.0, 14.0) vs. 5.0 (2.3, 9.0), <i>Z</i>=-3.61, <i>P</i>=0.014]. The severity of sialorrhea and deglutition disorders, along with the incidence of constipation, all increased with longer disease duration. Patients with the PIGD subtype had higher GCSI scores than those with the TD subtype [0.0 (0.0, 1.9) vs. 0.0 (0.0, 0.0), <i>Z</i>=-3.57, <i>P</i>=0.007]. Across the cohort, sialorrhea, deglutition disorders, gastroparesis, and constipation were positively associated with the H-Y stage, MDS-UPDRS Ⅰ, HAMD, NMSQ, and SCOPA-AUT; EAT-10 scores were negatively correlated with MoCA (<i>r</i>=-0.171, <i>P<</i>0.05); and GCSI scores were negatively correlated with MMSE and MoCA (<i>r</i>=-0.154, <i>r</i>=-0.169, both <i>P</i><0.05). <b>Conclusions:</b> Overall, 84.5% of the patients with PD had one or more gastrointestinal symptoms, and the incidence and severity of gastrointestinal symptoms increased with disease duration. The severity of gastroparesis was higher in the PIGD group than in the TD group. The scores of all gastrointestinal symptoms were positively correlated with the H-Y stage and MDS-UPDRS Ⅰ, while the GCSI scores were negatively correlated with the cogniti","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 7","pages":"635-642"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.3760/cma.j.cn112138-20250403-00198
Q L Chen, J C Lyu
{"title":"[Immunomodulatory effects and research progresses of budesonide enteric-coated capsules in IgA nephropathy].","authors":"Q L Chen, J C Lyu","doi":"10.3760/cma.j.cn112138-20250403-00198","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20250403-00198","url":null,"abstract":"","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 7","pages":"688-692"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}